MENU
+Compare
HTSUY
Stock ticker: OTC
AS OF
Nov 12 closing price
Price
$6.65
Change
-$0.15 (-2.21%)
Capitalization
1.89B

HTSUY stock forecast, quote, news & analysis

Hisamitsu Pharmaceutical Co Inc is a major pharmaceutical products manufacturer in Japan... Show more

HTSUY
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for HTSUY with price predictions
Nov 12, 2025

HTSUY in downward trend: price dove below 50-day moving average on November 12, 2025

HTSUY moved below its 50-day moving average on November 12, 2025 date and that indicates a change from an upward trend to a downward trend. In of 8 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HTSUY as a result. In of 14 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The 10-day moving average for HTSUY crossed bearishly below the 50-day moving average on November 12, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for HTSUY's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.084) is normal, around the industry mean (18.827). P/E Ratio (15.217) is within average values for comparable stocks, (71.764). HTSUY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.856). HTSUY has a moderately low Dividend Yield (0.012) as compared to the industry average of (0.031). P/S Ratio (1.920) is also within normal values, averaging (39.291).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. HTSUY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HTSUY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

A.I.Advisor
published Dividends

HTSUY paid dividends on June 10, 2024

Hisamitsu Pharmaceutical Co., Ltd. HTSUY Stock Dividends
А dividend of $0.07 per share was paid with a record date of June 10, 2024, and an ex-dividend date of February 28, 2024. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), Avadel Pharmaceuticals plc (NASDAQ:AVDL), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.14B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 1%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 32%. ORGO experienced the highest price growth at 63%, while MAJI experienced the biggest fall at -49%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -34%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -49%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 63
Price Growth Rating: 58
SMR Rating: 81
Profit Risk Rating: 90
Seasonality Score: 0 (-100 ... +100)
View a ticker or compare two or three
HTSUY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details